Logo of envhperEnvironmental Health PerspectivesBrowse ArticlesAbout EHPGeneral InformationAuthorsMediaProgramsPartnerships
Environ Health Perspect. 1998 May; 106(5): 267–271.
PMCID: PMC1533084
Research Article

N-acetylcysteine as an antidote in methylmercury poisoning.

N Ballatori, M W Lieberman, and W Wang
Author information ► Copyright and License information ►
This article has been cited by other articles in PMC.

Abstract

Methylmercury is a ubiquitous environmental pollutant and potent neurotoxin. Treatment of methylmercury poisoning relies almost exclusively on the use of chelating agents to accelerate excretion of the metal. The present study demonstrates that oral administration of N-acetylcysteine (NAC), a widely available and largely nontoxic amino acid derivative, produces a profound acceleration of urinary methylmercury excretion in mice. Mice that received NAC in the drinking water (10 mg/ml) starting at 48 hr after methylmercury administration excreted from 47 to 54% of the 203Hg in urine over the subsequent 48 hr, as compared to 4-10% excretion in control animals. When NAC-containing water was given from the time of methylmercury administration, it was even more effective at enhancing urinary methylmercury excretion and at lowering tissue mercury levels. In contrast, excretion of inorganic mercury was not affected by oral NAC administration. The ability of NAC to enhance methylmercury excretion when given orally, its relatively low toxicity, and is wide availability in the clinical setting indicate that it may be an ideal therapeutic agent for use in methylmercury poisoning.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (2.4M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.
 
icon of scanned page 267
267
icon of scanned page 268
268
icon of scanned page 269
269
icon of scanned page 270
270
icon of scanned page 271
271
 

Images in this article

Figure 1
Figure 1
on p.268
Figure 2
Figure 2
on p.268
Figure 3
Figure 3
on p.269
Figure 4
Figure 4
on p.269
Figure 5
Figure 5
on p.269
Figure 6
Figure 6
on p.269
Click on the image to see a larger version.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Bakir F, Damluji SF, Amin-Zaki L, Murtadha M, Khalidi A, al-Rawi NY, Tikriti S, Dahahir HI, Clarkson TW, Smith JC, et al. Methylmercury poisoning in Iraq. Science. 1973 Jul 20;181(4096):230–241. [PubMed]
  • Harada M. Minamata disease: methylmercury poisoning in Japan caused by environmental pollution. Crit Rev Toxicol. 1995;25(1):1–24. [PubMed]
  • Elhassani SB. The many faces of methylmercury poisoning. J Toxicol Clin Toxicol. 1982 Oct;19(8):875–906. [PubMed]
  • Clarkson TW, Magos L, Cox C, Greenwood MR, Amin-Zaki L, Majeed MA, Al-Damluji SF. Tests of efficacy of antidotes for removal of methylmercury in human poisoning during the Iraq outbreak. J Pharmacol Exp Ther. 1981 Jul;218(1):74–83. [PubMed]
  • Al-Abbasi AH, Kostyniak PJ, Clarkson TW. An extracorporeal complexing hemodialysis system for the treatment of methylmercury poisoning. III. Clinical applications. J Pharmacol Exp Ther. 1978 Oct;207(1):249–254. [PubMed]
  • Ishihara N, Shiojima S, Suzuki T. Selective enhancement of urinary organic mercury excretion by D-penicillamine. Br J Ind Med. 1974 Jul;31(3):245–249. [PMC free article] [PubMed]
  • Friedheim E, Corvi C. Meso-dimercaptosuccinic acid, a chelating agent for the treatment of mercury poisoning. J Pharm Pharmacol. 1975 Aug;27(8):624–626. [PubMed]
  • Magos L. The effects of dimercaptosuccinic acid on the excretion and distribution of mercury in rats and mice treated with mercuric chloride and methylmercury chloride. Br J Pharmacol. 1976 Apr;56(4):479–484. [PMC free article] [PubMed]
  • Magos L, Clarkson TW. The effect of oral doses of a polythiol resin on the excretion of methylmercury in mice treated with cysteine, D-penicillamine or phenobarbitone. Chem Biol Interact. 1976 Aug;14(3-4):325–335. [PubMed]
  • Gabard B. Improvement of oral chelation treatment of methyl mercury poisoning in rats. Acta Pharmacol Toxicol (Copenh) 1976 Aug;39(2):250–255. [PubMed]
  • Aaseth J. Mobilization of methyl mercury in vivo and vitro using N-acetyl-DL-penicillamine and other complexing agents. Acta Pharmacol Toxicol (Copenh) 1976 Sep;39(3):289–301. [PubMed]
  • Aaseth J, Frieheim EA. Treatment of methyl mercury poisoning in mice with 2,3-dimercaptosuccinic acid and other complexing thiols. Acta Pharmacol Toxicol (Copenh) 1978 Apr;42(4):248–252. [PubMed]
  • Zimmer LJ, Carter DE. The efficacy of 2,3-dimercaptopropanol and D-penicillamine on methyl mercury induced neurological signs and weight loss. Life Sci. 1978 Sep 11;23(10):1025–1034. [PubMed]
  • Planas-Bohne F. The influence of chelating agents on the distribution and biotransformation of methylmercuric chloride in rats. J Pharmacol Exp Ther. 1981 May;217(2):500–504. [PubMed]
  • Domingo JL. Prevention by chelating agents of metal-induced developmental toxicity. Reprod Toxicol. 1995 Mar-Apr;9(2):105–113. [PubMed]
  • Cantilena LR, Jr, Klaassen CD. The effect of chelating agents on the excretion of endogenous metals. Toxicol Appl Pharmacol. 1982 May;63(3):344–350. [PubMed]
  • Kostyniak PJ, Soiefer AI. A methylmercury toxicity model to test for possible adverse effects resulting from chelating agent therapy. J Appl Toxicol. 1984 Aug;4(4):206–210. [PubMed]
  • Aposhian HV, Maiorino RM, Gonzalez-Ramirez D, Zuniga-Charles M, Xu Z, Hurlbut KM, Junco-Munoz P, Dart RC, Aposhian MM. Mobilization of heavy metals by newer, therapeutically useful chelating agents. Toxicology. 1995 Mar 31;97(1-3):23–38. [PubMed]
  • Ewan KB, Pamphlett R. Increased inorganic mercury in spinal motor neurons following chelating agents. Neurotoxicology. 1996 Summer;17(2):343–349. [PubMed]
  • Ottenwälder H, Simon P. Differential effect of N-acetylcysteine on excretion of the metals Hg, Cd, Pb and Au. Arch Toxicol. 1987 Jul;60(5):401–402. [PubMed]
  • Henderson P, Hale TW, Shum S, Habersang RW. N-Acetylcysteine therapy of acute heavy metal poisoning in mice. Vet Hum Toxicol. 1985 Dec;27(6):522–525. [PubMed]
  • Girardi G, Elias MM. Effectiveness of N-acetylcysteine in protecting against mercuric chloride-induced nephrotoxicity. Toxicology. 1991 Apr 8;67(2):155–164. [PubMed]
  • Lorber A, Baumgartner WA, Bovy RA, Chang CC, Hollcraft R. Clinical application for heavy metal-complexing potential of N-acetylcysteine. J Clin Pharmacol. 1973 Aug-Sep;13(8):332–336. [PubMed]
  • Shum S, Skarbovig J, Habersang R. Acute lethal arsenite poisoning in mice: effect of treatment with N-acetylcysteine, D-penicillamine and dimercaprol on survival time. Vet Hum Toxicol. 1981;23(Suppl 1):39–42. [PubMed]
  • Godfrey NF, Peter A, Simon TM, Lorber A. IV N-acetylcysteine treatment of hematologic reactions to chrysotherapy. J Rheumatol. 1982 Jul-Aug;9(4):519–526. [PubMed]
  • Banner W, Jr, Koch M, Capin DM, Hopf SB, Chang S, Tong TG. Experimental chelation therapy in chromium, lead, and boron intoxication with N-acetylcysteine and other compounds. Toxicol Appl Pharmacol. 1986 Mar 30;83(1):142–147. [PubMed]
  • Endo A, Watanabe T. Analysis of protective activity of N-acetylcysteine against teratogenicity of heavy metals. Reprod Toxicol. 1988;2(2):141–144. [PubMed]
  • Ornaghi F, Ferrini S, Prati M, Giavini E. The protective effects of N-acetyl-L-cysteine against methyl mercury embryotoxicity in mice. Fundam Appl Toxicol. 1993 May;20(4):437–445. [PubMed]
  • Sheffner AL, Medler EM, Bailey KR, Gallo DG, Mueller AJ, Sarett HP. Metabolic studies with acetylcysteine. Biochem Pharmacol. 1966 Oct;15(10):1523–1535. [PubMed]
  • Hirayama K. Effects of combined administration of thiol compounds and methylmercury chloride on mercury distribution in rats. Biochem Pharmacol. 1985 Jun 1;34(11):2030–2032. [PubMed]
  • Kerper LE, Ballatori N, Clarkson TW. Methylmercury transport across the blood-brain barrier by an amino acid carrier. Am J Physiol. 1992 May;262(5 Pt 2):R761–R765. [PubMed]
  • Kostyniak PJ, Clarkson TW, Cestero RV, Freeman RB, Abbasi AH. An extracorporeal complexing hemodialysis system for the treatment of methylmercury poisoning. I. In vitro studies of the effects of four complexing agents on the distribution and dialyzability of methylmercury in human blood. J Pharmacol Exp Ther. 1975 Feb;192(2):260–269. [PubMed]
  • Toribara TY. Preparation of CH3 203HgCl of high specific activity. Int J Appl Radiat Isot. 1985 Nov;36(11):903–904. [PubMed]
  • Magos L, Clarkson TW. Atomic absorption determination of total, inorganic, and organic mercury in blood. J Assoc Off Anal Chem. 1972 Sep;55(5):966–971. [PubMed]
  • Tietze F. Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal Biochem. 1969 Mar;27(3):502–522. [PubMed]
  • Lewis PA, Woodward AJ, Maddock J. High-performance liquid chromatographic assay for N-acetylcysteine in plasma and urine. J Pharm Sci. 1984 Jul;73(7):996–998. [PubMed]
  • Hinchman CA, Matsumoto H, Simmons TW, Ballatori N. Intrahepatic conversion of a glutathione conjugate to its mercapturic acid. Metabolism of 1-chloro-2,4-dinitrobenzene in isolated perfused rat and guinea pig livers. J Biol Chem. 1991 Nov 25;266(33):22179–22185. [PubMed]
  • SHEFFNER AL. The reduction in vitro in viscosity of mucoprotein solutions by a new mucolytic agent, N-acetyl-L-cysteine. Ann N Y Acad Sci. 1963 Mar 30;106:298–310. [PubMed]
  • Prescott LF, Illingworth RN, Critchley JA, Stewart MJ, Adam RD, Proudfoot AT. Intravenous N-acetylcystine: the treatment of choice for paracetamol poisoning. Br Med J. 1979 Nov 3;2(6198):1097–1100. [PMC free article] [PubMed]
  • Borgström L, Kågedal B, Paulsen O. Pharmacokinetics of N-acetylcysteine in man. Eur J Clin Pharmacol. 1986;31(2):217–222. [PubMed]
  • Rodenstein D, DeCoster A, Gazzaniga A. Pharmacokinetics of oral acetylcysteine: absorption, binding and metabolism in patients with respiratory disorders. Clin Pharmacokinet. 1978 May-Jun;3(3):247–254. [PubMed]
  • Bonanomi L, Gazzaniga A. Toxicological, pharmacokinetic and metabolic studies on acetylcysteine. Eur J Respir Dis Suppl. 1980;111:45–51. [PubMed]
  • Morgan LR, Holdiness MR, Gillen LE. N-acetylcysteine: its bioavailability and interaction with ifosfamide metabolites. Semin Oncol. 1983 Mar;10(1 Suppl 1):56–61. [PubMed]
  • Shih VE, Schulman JD. N-acetylcysteine-cysteine disulfide excretion in the urine following N-acetylcysteine administration. J Pediatr. 1969 Jan;74(1):129–131. [PubMed]
  • Hannestad U, Sörbo B. Determination of 3-mercaptolactate, mercaptoacetate and N-acetylcysteine in urine by gas chromatography. Clin Chim Acta. 1979 Jul 16;95(2):189–200. [PubMed]
  • Hjortsø E, Fomsgaard JS, Fogh-Andersen N. Does N-acetylcysteine increase the excretion of trace metals (calcium, magnesium, iron, zinc and copper) when given orally? Eur J Clin Pharmacol. 1990;39(1):29–31. [PubMed]
Articles from Environmental Health Perspectives are provided here courtesy of National Institute of Environmental Health Science